BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NovaRx Corporation Announces $2.2 Million Award Of SBIR Grant To Help Fund Its Pivotal Phase II/III Clinical Trial In Brain Cancer


10/19/2005 5:11:17 PM

SAN DIEGO, May 12 /PRNewswire/ -- NovaRx Corporation announced today that it has been awarded $2.2 million in funding from the National Institutes of Health (NIH) via a new SBIR grant. This grant will provide a portion of the capital needed for the company to conduct a pivotal Phase II/III clinical trial to test the company's proprietary therapeutic vaccine to treat brain cancer, and is payable over a four year period. The company plans to initiate the pivotal brain cancer trial in 2005. NovaRx is currently in active discussions with both private investors and corporate partners to secure additional capital to complete the development of both its brain and lung cancer treatments, and to advance a therapeutic vaccine to treat colorectal cancer into mid-late stage development.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020204/LAM044LOGO )

"We are extremely pleased that the therapeutic approaches to treating cancers that are being developed by NovaRx continue to be recognized by the NIH as being important enough to be awarded additional funding," said Habib Fakhrai, Ph.D., NovaRx's President and CEO.

NovaRx is currently conducting a multi-center Phase II clinical trial treating individuals with advanced stages of lung cancer. The therapeutic vaccine being tested consists of non-small cell lung cancer cell lines that have been genetically modified with technology called transforming growth factor-beta (TGF-Beta) antisense. TGF-Beta is a potent agent commonly produced by cancer cells that helps the cells hide from the immune system. TGF-Beta antisense is a technology that blocks the production of TGF-Beta by the cancer cells. NovaRx Corporation holds the exclusive worldwide license for this technology for the treatment and prevention of numerous cancers.

NovaRx Corporation is a biopharmaceutical company based in San Diego, California. The company is dedicated to developing new therapeutic approaches for treating cancer and is presently focused on lung cancer, which is responsible for approximately 170,000 deaths in the U.S. alone each year and is the number one cause of cancer death throughout the world, and brain cancer, which affects approximately 1 million individuals worldwide.

For more information on the company, please visit their website at http://www.novarx-pharma.com/

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020204/LAM044LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comNovaRx Corporation

CONTACT: Leanne Shawler of NovaRx, +1-858-638-0881



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES